OpenAI acquires Orchestra Bio in AI push for new drugs

OpenAI has acquired Orchestra Bio, a startup focused on developing AI agents to assist pharmaceutical companies in managing drug development, according to Axios. This acquisition is significant as both OpenAI and Anthropic, rival AI companies, are expanding beyond their core competencies in coding and cybersecurity to venture into science.

OpenAI plans to integrate Orchestra's team and technology into its Rosalind suite, a collection of AI models and tools designed for life sciences researchers. Orchestra's platform allows scientists to delegate tasks such as monitoring studies, tracking drug development timelines, and identifying potential delays to AI agents. Both OpenAI and Anthropic aim to deploy agents that can connect scientific findings with the necessary decisions and next steps to advance potential treatments.

Financial details of the acquisition were not disclosed. The acquisition comes as AI companies seek to demonstrate their potential to tackle critical issues like curing cancer and transforming industries. Anthropic recently acquired AI biotech startup Coefficient Bio for around $400 million.

OpenAI has integrated its Rosalind model, introduced in April, to help researchers tackle complex problems in biology, chemistry, and drug discovery. The company has also partnered with pharmaceutical giants like Novo Nordisk and Moderna to bring AI into research and development workflows. OpenAI estimates that developing a new medicine typically takes 10 to 15 years, a process it believes AI can expedite.

Anthropic has also been aggressively pursuing life sciences. In June, they launched Claude Science, an AI-powered research platform connecting scientific databases, analysis tools, and specialized agents. In September, Anthropic announced a new biological research lab, claiming that Claude had discovered a previously unknown enzyme system with similarities to CRISPR. However, some scientists questioned the significance of this discovery, as reported by Bloomberg.

The overall trend in the AI race is shifting from developing the best models to applying that intelligence across various industries. Several AI investors believe that a key question for AI companies going public will be their ability to expand into new markets.